Medipost said Monday that it has signed a cooperation agreement with LG Chem for developing gene stem cell therapy.
Under the accord, the two companies will conduct research to find a stem cell drug candidate for the next two years.
Medipost will be responsible for developing and delivering umbilical cord blood-derived mesenchymal stem cells, while LG Chem will take charge in selecting the genes that cause disease and stem cell generation using genetic engineering techniques.
"Through this joint research, we will be able to utilize LG Chem's excellent gene search and infusion ability and development know-how in the development of therapeutic drugs," a Medipost company official said. "We will develop a treatment that will reduce the burden on patients with the aim of removing the root cause of the disease."
<© Korea Biomedical Review, All rights reserved.>